| Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ... JAMA neurology 76 (9), 1035-1048, 2019 | 603 | 2019 |
| Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies G Luna, P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, ... JAMA neurology 77 (2), 184-191, 2020 | 456 | 2020 |
| Monitoring disease activity in multiple sclerosis using serum neurofilament light protein L Novakova, H Zetterberg, P Sundström, M Axelsson, M Khademi, ... Neurology 89 (22), 2230-2237, 2017 | 429 | 2017 |
| Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab M Gunnarsson, C Malmeström, M Axelsson, P Sundström, C Dahle, ... Annals of neurology 69 (1), 83-89, 2011 | 408 | 2011 |
| An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study P Sundstrom, P Juto, G Wadell, G Hallmans, A Svenningsson, L Nystrom, ... Neurology 62 (12), 2277-2282, 2004 | 402 | 2004 |
| Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy J Salzer, R Svenningsson, P Alping, L Novakova, A Björck, K Fink, ... Neurology 87 (20), 2074-2081, 2016 | 391 | 2016 |
| Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells H Hammarberg, O Lidman, C Lundberg, SY Eltayeb, AW Gielen, ... Journal of Neuroscience 20 (14), 5283-5291, 2000 | 372 | 2000 |
| Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ... The Lancet Neurology 19 (4), 307-316, 2020 | 325 | 2020 |
| Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ... Neurology 89 (11), 1117-1126, 2017 | 283 | 2017 |
| Neurofilament and glial fibrillary acidic protein in multiple sclerosis N Norgren, P Sundstrom, A Svenningsson, L Rosengren, T Stigbrand, ... Neurology 63 (9), 1586-1590, 2004 | 281 | 2004 |
| Rituximab versus fingolimod after natalizumab in multiple sclerosis patients P Alping, T Frisell, L Novakova, P Islam‐Jakobsson, J Salzer, A Björck, ... Annals of neurology 79 (6), 950-958, 2016 | 247 | 2016 |
| Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ... Neurology 89 (11), 1107-1116, 2017 | 239 | 2017 |
| Neurofilament light as a prognostic marker in multiple sclerosis J Salzer, A Svenningsson, P Sundström Multiple Sclerosis Journal 16 (3), 287-292, 2010 | 229 | 2010 |
| Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience J Burman, E Iacobaeus, A Svenningsson, J Lycke, M Gunnarsson, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (10), 1116-1121, 2014 | 227 | 2014 |
| Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis M Granqvist, M Boremalm, A Poorghobad, A Svenningsson, J Salzer, ... JAMA neurology 75 (3), 320-327, 2018 | 210 | 2018 |
| Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS J Bergman, A Dring, H Zetterberg, K Blennow, N Norgren, J Gilthorpe, ... Neurology: Neuroimmunology & Neuroinflammation 3 (5), e271, 2016 | 162 | 2016 |
| Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid A Svenningsson, O Andersen, M Edsbagge, S Stemme Journal of neuroimmunology 63 (1), 39-46, 1995 | 157 | 1995 |
| Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies T Spelman, M Magyari, F Piehl, A Svenningsson, PV Rasmussen, M Kant, ... JAMA neurology 78 (10), 1197-1204, 2021 | 155 | 2021 |
| Comparative assessment of the prognostic value of biomarkers in traumatic brain injury reveals an independent role for serum levels of neurofilament light F Al Nimer, E Thelin, H Nyström, AM Dring, A Svenningsson, F Piehl, ... PloS one 10 (7), e0132177, 2015 | 149 | 2015 |
| Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis M Axelsson, C Malmeström, M Gunnarsson, H Zetterberg, P Sundström, ... Multiple Sclerosis Journal 20 (1), 43-50, 2014 | 147 | 2014 |
